The coronavirus pandemic has had a major financial impact on the world’s capital markets. However, some biopharma companies have seen this as an opportunity for unprecedented growth in value.

Financial data from GlobalData’s Pharma Intelligence Center Companies Database reveals that small cap ($0.3–2.0B) public companies working on the development of a Covid-19 drug are witnessing growth in market cap among the plunge of other industries.